Modern prostate brachytherapy
TL;DR: Early brachytherapy represents the oldest technique for delivering radiation to the prostate gland, preceding external beam therapy of the prostate by several decades.
read more
Abstract: Of all the treatment options available for men with organ-confined prostate cancer, brachytherapy--permament implantation of radioactive seeds into the prostate gland--is the least disruptive for the patient, both physiologically and practically. Early brachytherapy represents the oldest technique for delivering radiation to the prostate gland, preceding external beam therapy of the prostate by several decades. Although there have not been, and are not likely to be, any definitive randomized studies comparing radical prostatectomy, external beam radiotherapy, and brachytherapy, treatment decisions will continue to be made on the basis of patient and physician preferences in conjunction with clinical probabilities. Long-term results in this series show that monotherapy with seed implants achieved disease-free survival of 66%; moreover, 79% of patients with higher grade disease who were treated with a combination of brachytherapy and external beam radiation also experienced long-term disease-free survival. The following article provides a brief historical review of prostate brachytherapy, rationale for treatments, patient selection criteria, up-to-date implant techniques, and long-term (12-year) outcome results.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A history of prostate cancer treatment
TL;DR: The increased incidence of prostate cancer has led to remarkable changes in diagnosis and treatment over the past century, and how did these evolve into the variety of therapeutic strategies from which patients have to choose today?
648
Brachytherapy: An overview for clinicians
Cyrus Chargari,Eric Deutsch,Eric Deutsch,Eric Deutsch,Pierre Blanchard,Sebastien Gouy,Hélène Martelli,Florent Guérin,Isabelle Dumas,Alberto Bossi,Philippe Morice,Philippe Morice,Akila N. Viswanathan,Christine Haie-Meder +13 more
TL;DR: The clinical relevance of brachytherapy is discussed with a focus on indications, levels of evidence, and results in the overall context of radiation use for patients with cancer.
244
“MRI Stealth” robot for prostate interventions
Dan Stoianovici,Danny Y. Song,Doru Petrisor,Daniel Ursu,Dumitru Mazilu,Michael Mutener,Michael Schär,Alexandru Patriciu +7 more
TL;DR: The robot is the first to show the feasibility of fully automated in‐scanner interventions of MRI‐guided prostate interventions, and the challenges of MRI robot compatibility are given and the solutions adopted in making the MrBot are presented.
236
Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer.
Michael W. Kattan,Louis Potters,John C. Blasko,David C. Beyer,Paul A. Fearn,William Cavanagh,Steve Leibel,Peter T. Scardino +7 more
TL;DR: A nomogram that predicts the probability of remaining free from biochemical recurrence for 5 years after brachytherapy without adjuvant hormonal therapy was developed using Cox proportional hazards regression analysis.
210
Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer.
TL;DR: For patients with clinical stage T1c or T2 disease and a Gleason score of less than 8, 5-year biochemical disease-free survival is remarkably similar for all the above treatments, and complication rates are acceptable for all these modalities.
147
References
Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer
Anthony V. D'Amico,R. Whittington,S.B. Malkowicz,Daniel Schultz,Kenneth R. Blank,Gregory A. Broderick,John E. Tomaszewski,Andrew A. Renshaw,Irving D. Kaplan,Clair J. Beard,Alan J. Wein +10 more
TL;DR: Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high- risk patients treated with RP or RT did better then those treated by implant.
4.2K
Cancer statistics, 1999.
TL;DR: The Surveillance Research Program of the American Cancer Society's Department of Epidemiology and Surveillance Research reports its 33rd annual compilation of cancer frequency, incidence, mortality, and survival data for the United States.
Impotence Following Radical Prostatectomy: Insight into Etiology and Prevention.
TL;DR: Impotence after radical prostatectomy results from injury to the pelvic nerve plexus that provides autonomic innervation to the corpora cavernosa, and refinements in surgical technique, especially during ligation of the lateral pedicle and apical dissection, can prevent this complication.
1.4K
The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer
Alan W. Partin,John Yoo,H. Ballentine Carter,Jay D. Pearson,Daniel W. Chan,Jonathan I. Epstein,Patrick C. Walsh +6 more
TL;DR: From these analyses probability plots and nomograms have been constructed to assist urologists in the preoperative prediction of final pathological stage for patients with clinically localized prostate cancer.
1.3K